EIP is delighted to announce a NEW free-to-access webinar on Spotting the Signs of Mucopolysaccharidosis (MPS)  

A Step-by-Step Approach - Spotting the Early Signs of MPS


13 April 2022 


The webinar is now organised. Register to access the video. 

  Can't attend the live event? By registering, you will receive a link to the on-demand version after the session concludes.   


  Misdiagnosis of Mucopolysaccharidosis (MPS) results in late diagnosis and the late start of treatment, which has significant consequences on long-term outcomes. This gap usually results in confusing symptoms with other conditions, most notably trying to address symptoms directly and therefore delaying actual diagnosis and treatment, or referring the patient to the wrong pediatric specialties causing further delays in the condition’s management chain.  
  Language: English ● Duration: 30 minutes followed by questions from the audience  
  Presenter: Maurizio Scarpa, Regional Coordinating Center for Rare Diseases Udine University Hospital, Udine, Italy  


  This educational activity is designed for an international audience of General Pediatricians, General Practitioners, Pediatric Endocrinologists, Pediatric Rheumatologists and other physicians and healthcare professionals with an interest in Metabolic Diseases.  


  ✓ Preparing you to ’think rare’ and think of MPS as a possible diagnosis by deconstructing the early signs and symptoms   
  ✓ What diagnostic steps should you take to refer a patient to avoid referrals to the wrong specialists?   
  ✓ Reviewing the main musculoskeletal manifestations of mucopolysaccharidoses   
  ✓ Examining how to recognise signs of metabolic disease and what these look like in practice   
  ✓ MPS diagnosis musculoskeletal case study - diagnosis in action  

Click below to start your free registration



The Spot the Early Signs program aims to fight under-diagnosed or late-diagnosed conditions for which treatments are available and where early detection and early treatment could make a significant difference in the condition's development, the quality of life and the survival of patients.